They also observed that experimental depletion of SMARCA4 led to decreased cell viability in MAX-deficient cells, setting the background for potential therapeutic strategies in SCLC demonstrating MAX deficiency [23]. This evidence concerns the gene SMARCA4 and small cell lung carcinoma.